@metacollectiveG@kevinjsears@joostverhoeff@NeuroOnc I would love to see all patients who use dcvax to be followed in a regulatory grade registry after approval so we can learn from every patient’s experience and figure out the right combos fast
Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma presented by prof Linda Liau at #sno2022@NeuroOnc
https://t.co/VfEl4MAtYC
This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated with improved survival in both newly diagnosed & recurrent glioblastoma compared with matched controls who received SOC treatment. https://t.co/bOPFizkLQ5
@saugarmaripuri I’ve been in a “waiting room” on the website for almost 3 hours trying to get my father in law an appointment. Not complaining, just reporting. We will continue to wait, but totally agree with you sir.